Marshall L. Nash

Neurology

2665 N Decatur Rd
Suite 540
Decatur, GA 30033

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.

Journal: The journal of prevention of Alzheimer's disease

Published: January 03, 2025

Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study.

Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study.

Journal: Journal of rehabilitation medicine

Published: November 06, 2015

Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury.

Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury.

Journal: Journal of neurotrauma

Published: October 16, 2015

Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.

Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.

Journal: Journal of the peripheral nervous system : JPNS

Published: November 14, 2014

Showing 1-4 of 4

Last Updated: 09/26/2026